

Virology screening

In line with UKCB guidance all new patients referred for systemic anti-cancer treatment should be screened for hepatitis B and C and the result reviewed prior to the start of treatment. Patients not previously tested who are starting a new line of treatment, should also be screened for hepatitis B and C. All relevant protocols will be updated with this requirement at their next review.

For full guidance see:

<https://www.ukchemotherapyboard.org/position-statements>